Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD
Open accessThe DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
Context: Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and associated with significant morbidity and mortality. Thyroid hormone (TH) increases β-oxidation of fatty acids and decreases intrahepatic lipid content (IHLC) in rodents with NAFLD. Objective: We investigated the possibility of low intrahepatic TH concentration in NAFLD and studied the effect of TH treatment in humans. Design/Setting: This was a phase 2b single-arm study in six hospitals in Singapore. Intrahepatic thyroid hormone concentrations were measured in rats with induced NAFLD. Patients: Euthyroid patients with T2DM and steatosis measured by ultrasonography. Intervention: Levothyroxine was titrated to reach a thyroid-stimulating hormone level of 0.34 to 1.70 mIU/L before a 16-week maintenance phase. Main Outcome Measures: The primary outcome measure was change in IHLC measured by proton magnetic resonance spectroscopy after treatment. Results: Twenty male patients were included in the per-protocol analysis [mean ± SD: age, 47.8 ± 7.8 years; body mass index (BMI), 30.9 ± 4.4 kg/m2; baseline IHLC, 13% ± 4%]. After treatment, IHLC was decreased 12% (±SEM, 26%) relative to baseline (absolute change, -2%; 95% CI, -3 to 0; P = 0.046). Small decreases in BMI (P = 0.044), visceral adipose tissue volume (P = 0.047), and subcutaneous adipose tissue volume (P = 0.045) were observed. No significant changes in glucose regulation or lipid profile occurred. Conclusion: This study demonstrated the efficacy and safety of low-dose TH therapy for NAFLD in men. TH or TH analogs may be beneficial for this condition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In humans, hypothyroidism is associated with a poor prognosis in established heart failure (33) and TH can reduce intrahepatic triglyceride content (34,35).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [35]
In the citing paper
“Indeed, low-dose LT4 reduces intrahepatic lipid content in patients with type 2 diabetes mellitus and metabolic (dysfunction)-associated fatty liver disease (77), whereas the opposite is observed in patients with resistance to TH (78).”
From Emerging Therapies in Hypothyroidism (2024) · cites this paper as [77]
In the citing paper
“LT4 also reduced intrahepatic lipid content in an uncontrolled study in euthyroid subjects with non-alcoholic fatty liver disease and type 2 diabetes”
From Pharmacodynamic and Therapeutic Actions of Levothyroxine (2021) · cites this paper as [45]
In the citing paper
“and TH can reduce intrahepatic triglyceride content [34, 35].”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [35]
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Szczepaniak, L. S., Nurenberg, P., Leonard, D., Browning, J. D., Reingold, J. S., Grundy, S., Hobbs, H. H., & Dobbins, R. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,562
The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux
Samuel, V. T., & Shulman, G. I. (2016) · Journal of Clinical Investigation · doi:10.1172/jci77812 · Cited by 1,484
Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164
Petersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911
Direct effects of thyroid hormones on hepatic lipid metabolism
Sinha, R. A., Singh, B. K., & Yen, P. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.10 · Cited by 660
Self-citationTargher, G., Bertolini, L., Poli, F., Rodella, S., Scala, L., Tessari, R., Zenari, L., & Falezza, G. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3541 · Cited by 574
Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biernacki, D., Orsak, B., Subbarayan, S., Webb, A., Hecht, J., & Cusi, K. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1966 · Cited by 503
Studies of insulin resistance in patients with clinical and subclinical hypothyroidism
Maratou, E., Hadjidakis, D. J., Kollias, A., Tsegka, K., Peppa, M., Alevizaki, M., Mitrou, P., Lambadiari, V, Boutati, E., Nikzas, D., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-08-0797 · Cited by 455
Cited by
Sinha, R. A., Bruinstroop, E., Singh, B. K., & Yen, P. M. (2019) · Thyroid · doi:10.1089/thy.2018.0664 · Cited by 271
Self-citationHutchison, A. L., Tavaglione, F., Romeo, S., & Charlton, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.030 · Cited by 250
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Thyroid hormone signaling and the liver
Ritter, M. J., Amano, I., Hollenberg, A. N., et al. (2020) · Hepatology · doi:10.1002/hep.31296 · Cited by 188
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0720 · Cited by 172
The first MASH drug therapy on the horizon: Current perspectives of resmetirom
Petta, S., Targher, G., Romeo, S., Pajvani, U. B., Zheng, M., Aghemo, A., & Valenti, L. V. C. (2024) · Liver International · doi:10.1111/liv.15930 · Cited by 171
Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD
Mavromati, M., & Jornayvaz, F. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312797 · Cited by 171
Karim, G., Department of Medicine, M. S. I., Bansal, M. B., & Division of Liver Diseases, D. O. M. (2023) · European Endocrinology · doi:10.17925/ee.2023.19.1.60 · Cited by 135
Mantovani, A., Nascimbeni, F., Lonardo, A., Zoppini, G., Bonora, E., Mantzoros, C. S., & Targher, G. (2018) · Thyroid · doi:10.1089/thy.2018.0257 · Cited by 153
NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome
Rosato, V., Masarone, M., Dallio, M., Federico, A., Aglitti, A., & Persico, M. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16183415 · Cited by 166
Subclinical Hypothyroidism in Patients with Obesity and Metabolic Syndrome: A Narrative Review
Biondi, B. (2023) · Nutrients · doi:10.3390/nu16010087 · Cited by 152
Metabolic Messengers: Thyroid Hormones
Sinha, R. A., & Yen, P. M. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00986-0 · Cited by 134
Self-citationRatziu, V., Scanlan, T. S., & Bruinstroop, E. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.10.018 · Cited by 128
Self-citationLonardo, A., Mantovani, A., Lugari, S., & Targher, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112841 · Cited by 120
NAFLD and thyroid function: pathophysiological and therapeutic considerations
Hatziagelaki, E., Paschou, S. A., Schön, M., Psaltopoulou, T., & Roden, M. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.08.001 · Cited by 93
“Histological evaluation of the liver biopsy: for example, NAS score Abbreviations: eGFR, estimated glomerular filtration rate; FIB-4, fibrosis 4; FLI, fibrosis liver index; FT4, free thyroxine; g, grams; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; 1H-MRS, protonmagnetic resonance spectroscopy; HOMA-IR,…”
BackgroundInfluentialZhou, J., Tripathi, M., Ho, J. P., Widjaja, A. A., Shekeran, S. G., Camat, M. D., James, A., Wu, Y., Ching, J., Kovalik, J., et al. (2022) · Thyroid · doi:10.1089/thy.2021.0621 · Cited by 89
Self-citationPathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?
Lonardo, A., Ballestri, S., Mantovani, A., Nascimbeni, F., Lugari, S., & Targher, G. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.12.014 · Cited by 73
Pathophysiology of NASH in endocrine diseases
Gariani, K., & Jornayvaz, F. R. (2021) · Endocrine Connections · doi:10.1530/ec-20-0490 · Cited by 87
Kim, D., Vazquez-Montesino, L. M., Escober, J. A., Fernandes, C. T., Cholankeril, G., Loomba, R., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000654 · Cited by 76
Actions of thyroid hormones and thyromimetics on the liver
Sinha, R. A., Bruinstroop, E., & Yen, P. M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00991-4 · Cited by 81
Self-citationTănase, D. M., Gosav, E. M., Neculae, E., Costea, C. F., Ciocoiu, M., Hurjui, L. L., Tărniceriu, C. C., & Floria, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165927 · Cited by 79
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · European Thyroid Journal · doi:10.1159/000512970 · Cited by 78
Reduced expression of thyroid hormone receptor β in human nonalcoholic steatohepatitis
Krause, C., Grohs, M., El Gammal, A. T., Wolter, S., Lehnert, H., Mann, O., Mittag, J., & Kirchner, H. (2018) · Endocrine Connections · doi:10.1530/ec-18-0499 · Cited by 70
Diagnosis and treatment of hypothyroidism in the elderly
Duntas, L. H., & Yen, P. M. (2019) · Endocrine · doi:10.1007/s12020-019-02067-9 · Cited by 74
Self-citationAutophagy Dysregulation in Metabolic Associated Fatty Liver Disease: A New Therapeutic Target
Chen, C., & Lin, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710055 · Cited by 66
Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression
Bruinstroop, E., Zhou, J., Tripathi, M., Yau, W. W. Y., Boelen, A., Singh, B. K., & Yen, P. M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101266 · Cited by 65
Self-citationThyroid hormone action and liver disease, a complex interplay
Marino, L., Kim, A., Ni, B., & Celi, F. S. (2023) · Hepatology · doi:10.1097/hep.0000000000000551 · Cited by 63
A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia
Zhou, J., Waskowicz, L. R., Lim, A., Liao, X.-H., Lian, B., Masamune, H., Refetoff, S., Tran, B., Koeberl, D. D., & Yen, P. M. (2019) · Thyroid® · doi:10.1089/thy.2019.0007 · Cited by 60
Self-citationBruinstroop, E., van der Spek, A. H., & Boelen, A. (2023) · European Thyroid Journal · doi:10.1530/etj-22-0211 · Cited by 59
Self-citationManka, P. P., Bechmann, L. P., Best, J., Sydor, S., Claridge, L. C., Coombes, J. D., Canbay, A. E., Moeller, L. C., Gerken, G., Wedemeyer, H. H., et al. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-05687-3 · Cited by 59
Thyroid Hormones and Metabolism Regulation: Which Role on Brown Adipose Tissue and Browning Process?
Sabatino, L., & Vassalle, C. (2025) · Biomolecules · doi:10.3390/biom15030361 · Cited by 59
Mantovani, A., Csermely, A., Bilson, J., Borella, N., Enrico, S., Pecoraro, B., Shtembari, E., Morandin, R., Pοlyzos, S. A., Valenti, L. V. C., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332491 · Cited by 57
Increased Hepatic Fat Content in Patients with Resistance to Thyroid Hormone Beta
Chaves, C., Bruinstroop, E., Refetoff, S., Yen, P. M., & Anselmo, J. (2021) · Thyroid® · doi:10.1089/thy.2020.0651 · Cited by 55
Self-citationUnderstanding the Relationship between Nonalcoholic Fatty Liver Disease and Thyroid Disease
Vidal‐Cevallos, P., Gall, S. M.-B., Uribe, M., & Chávez-Tapia, N. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914605 · Cited by 54
Molecular links between non-alcoholic fatty liver disease and hepatocellular carcinoma
Raza, S., Rajak, S., Anjum, B., & Sinha, R. A. (2019) · Hepatoma Research · doi:10.20517/2394-5079.2019.014 · Cited by 54
Self-citationKizivat, T., Marić, I., Mudri, D., Bilić-Čurčić, I., Primorac, D., & Smolić, M. (2020) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2020.00027 · Cited by 52
Ramanathan, R., Patwa, S. A., Ali, A. H., & Ibdah, J. A. (2023) · Cells · doi:10.3390/cells12242806 · Cited by 51
Ruissen, M. M., Mak, A. L., Beuers, U., Tushuizen, M. E., & Holleboom, A. G. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0065 · Cited by 43
Emerging Therapies in Hypothyroidism
Bianco, A. C. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-060622-101007 · Cited by 44
Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
Wirth, E. K., Puengel, T., Spranger, J., & Tacke, F. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2110864 · Cited by 42
“visceral and subcutaneous adipose tissue without obvious side effects [67].”
BackgroundA coregulator shift, rather than the canonical switch, underlies thyroid hormone action in the liver
Shabtai, Y., Nagaraj, N. K., Batmanov, K., Cho, Y., Guan, Y., Jiang, C., Remsberg, J. R., Forrest, D., & Lazar, M. A. (2021) · Genes & Development · doi:10.1101/gad.345686.120 · Cited by 38
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
Vitulo, M., Gnodi, E., Rosini, G., Meneveri, R., Giovannoni, R., & Barisani, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612748 · Cited by 37
Metabolic and Functional Cross Talk Between the Thyroid and Liver
Chng, C. L., Goh, G. B., & Yen, P. M. (2025) · Thyroid · doi:10.1089/thy.2025.0178 · Cited by 38
Self-citationNonalcoholic Fatty Liver Disease and Endocrine Axes—A Scoping Review
von Hafe, M., Borges‐Canha, M., Vale, C., Leite, A. R., Neves, J. S., Carvalho, D. M., & Leite-Moreira, A. F. (2022) · Metabolites · doi:10.3390/metabo12040298 · Cited by 37
Pοlyzos, S. A., & Targher, G. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16117 · Cited by 33
Potential therapeutic strategies for MASH: from preclinical to clinical development
Xie, Z., Li, Y., Cheng, L., Huang, Y., Rao, W., Shi, H., & Li, J. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae029 · Cited by 33
Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Implications
Sîngeap, A.-M., Stanciu, C., Huiban, L., Muzica, C. M., Cuciureanu, T., Gîrleanu, I., Chiriac, S. A., Zenovia, S., Năstasă, R., Sfarti, C. V., et al. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/6678142 · Cited by 33
Alternative Etiologies of Liver Disease in Children With Suspected NAFLD
Yodoshi, T., Orkin, S. H., Arce‐Clachar, A. C., Bramlage, K., Xanthakos, S. A., Valentino, P. L., & Mouzaki, M. (2021) · PEDIATRICS · doi:10.1542/peds.2020-009829 · Cited by 31
TSH Levels as an Independent Risk Factor for NAFLD and Liver Fibrosis in the General Population
Martínez-Escudé, A., Pera, G., Costa-Garrido, A., Rodríguez, L., Arteaga, Í., Expósito-Martínez, C., Torán‐Monserrat, P., & Caballería, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132907 · Cited by 31
Effects of Thyroid Hormones on Lipid Metabolism Pathologies in Non-Alcoholic Fatty Liver Disease
Liao, C., Huang, P.-S., Chien, H., Lin, T.-K., Yeh, C., & Lin, K. (2022) · Biomedicines · doi:10.3390/biomedicines10061232 · Cited by 31
Marschner, R. A., Arenhardt, F. K., Ribeiro, R. T., & Wajner, S. M. (2022) · Metabolites · doi:10.3390/metabo12080675 · Cited by 32
Thyroid Function and the Risk of Non-Alcoholic Fatty Liver Disease in Morbid Obesity
Borges‐Canha, M., Neves, J. S., Mendonça, F. M., Silva, M. M., Costa, C. F., Cabral, P. M., Guerreiro, V. A., Lourenço, R., Meira, P., Salazar, D. A., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.572128 · Cited by 30
Li, Z., Zheng, D., Zhang, T., Ruan, S., Li, N., Yang, Y., Yang, P., & Wang, D. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000343 · Cited by 29
Pu, S., Zhao, B., Jiang, Y., & Cui, X. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02474-0 · Cited by 27
Endoplasmic reticulum stress at the forefront of fatty liver diseases and cancer
Karin, M., & Kim, J. Y. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100096 · Cited by 28
Targeting nuclear receptors for NASH/MASH: From bench to bedside
Sinha, R. A. (2024) · Liver Research · doi:10.1016/j.livres.2024.03.002 · Cited by 23
Self-citationThe roles of autophagy and thyroid hormone in the pathogenesis and treatment of NAFLD
Zhou, J., Sinha, R. A., & Yen, P. M. (2021) · Hepatoma Research · doi:10.20517/2394-5079.2021.82 · Cited by 22
Self-citationThyromimetics and MASLD: Unveiling the Novel Molecules Beyond Resmetirom
Ezhilarasan, D. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16874 · Cited by 20
Kouvari, M., Valenzuela‐Vallejo, L., Axarloglou, E., Verrastro, O., Papatheodoridis, G., Mingrone, G., George, J., & Mantzoros, C. S. (2024) · Liver International · doi:10.1111/liv.15847 · Cited by 18
Thyroid hormones and thyromimetics: a new approach to nonalcoholic steatohepatitis?
Sinha, R. A., Bruinstroop, E., Singh, B. K., & Yen, P. M. (2020) · Hepatology · doi:10.1002/hep.31204 · Cited by 17
“(6) Thus, it is possible that low-dose levothyroxine (T4) may be effective to treat hepatosteatosis and early NASH,(6) whereas low-dose T3 or thyromimetics that do not undergo DIO1 deiodination may be more useful for later stages of NASH.”
BackgroundSelf-citationLiu, C., Zeng, Q., Hu, T., Huang, Y., Song, Y., Guan, H., Rockey, D. C., Tang, H. C., & Li, S. (2025) · Portal hypertension & cirrhosis · doi:10.1002/poh2.100 · Cited by 15
Gor, R., Siddiqui, N. A., Fernando, R. W., Nair, A. S., Illango, J., Malik, M., & Hamid, P. (2021) · Cureus · doi:10.7759/cureus.14858 · Cited by 15
Marschner, R. A., Roginski, A. C., Ribeiro, R. T., Longo, L., de Freitas, L. B. R., Alvares-da-Silva, M., & Wajner, S. M. (2023) · Cells · doi:10.3390/cells12071022 · Cited by 15
López‐Alcántara, N., Oelkrug, R., Sentis, S. C., Kirchner, H., & Mittag, J. (2023) · iScience · doi:10.1016/j.isci.2023.108064 · Cited by 15
Increasing Liver Fat Is Associated With Incident Cardiovascular Risk Factors
Brunner, K. T., Pedley, A., Massaro, J. M., Hoffmann, U., Benjamin, E. J., & Long, M. T. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.08.003 · Cited by 15
The correlation between triiodothyronine and the severity of liver fibrosis
He, W., Huang, C., Wang, L., Su, W., Wang, S., Huang, P., Zhang, X., Huang, Y., Zhao, Y., Lin, M., et al. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01228-8 · Cited by 14
Liu, L., Li, P., Mi, Y., Liu, Y., Liu, Y., & Zhang, P. (2019) · Medicine · doi:10.1097/md.0000000000017945 · Cited by 14
Tan, Y. C. R. S., Tang, X., Mu, P., Yang, Y., Li, M., Nie, Y., Li, H., Zhu, Y., & Chen, Y. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s313224 · Cited by 13
Barrientos‐Riosalido, A., Real, M., Bertran, L., Aguilar, C., Martínez, S., Parada, D., Vives, M., Sabench, F., Riesco, D., Castillo, D. D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021324 · Cited by 13
FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
Azam, M. M., Mukhtar, S., Haris, M., Laique, F., Amir, S., Mohiuddin, M., & Giri, B. (2024) · Exploration of Drug Science · doi:10.37349/eds.2024.00078 · Cited by 12
Kahaly, G. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-63277-9 · Cited by 12
Huang, Y., Xia, X., Xu, J., Wang, Z., You, Y., & Du, Q. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13664 · Cited by 11
Sinha, R. A. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2068 · Cited by 10
Self-citationLiu, M., Ma, Y., Cheang, W. S., Su, Z., & Xu, S. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.011 · Cited by 11
Jin, X., Song, S. J., Lai, J. C., Wong, G. L., Kong, A. P. S., Peng, N., Xiao, X., Wong, V. W., & Yip, T. C. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0860 · Cited by 9
Naujack, A.-M., Krause, C., Britsemmer, J. H., Taege, N., Mittag, J., & Kirchner, H. (2024) · European Thyroid Journal · doi:10.1530/etj-24-0080 · Cited by 9
Impact of peripheral thyroid hormone balance on liver fat: insights from the NutriAct trial
Sommer, M., Nguyen, T.-H., Pletsch‐Borba, L., Wernicke, C., Tacke, F., Schwerdtle, T., Pellowski, D., Machann, J., Spranger, J., Wirth, E. K., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae093 · Cited by 6
Xiao, J., Zhu, C., Zhang, X., Sun, L., Gao, C., Liang, X., He, Q., & Liu, M. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej21-0536 · Cited by 6
Levothyroxine and Non-alcoholic Fatty Liver Disease: A Mini Review
Singha, P. S., Ghosh, S., & Ghosh, D. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666230314113543 · Cited by 6
Sugawara, T., Hitaka, K., Matsumoto, M., Nakamura, S., Kobayashi, R., Kandori, H., & Nio, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-24927-3 · Cited by 5
Capuccio, S., Privitera, G., Scilletta, S., Rocca, F. L., Marco, M. D., Scicali, R., Pino, A. D., Piro, S., & Russello, M. (2026) · Liver International · doi:10.1111/liv.70431 · Cited by 5
Liu, Q., Li, H., He, W., Zhao, Q. C., Huang, C., Wang, Q., Zheng, Z., Zhang, X., Shi, X., & Li, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1075986 · Cited by 5
Pharmacodynamic and Therapeutic Actions of Levothyroxine
Hennessey, J. V. (2021) · 70 Years of Levothyroxine · doi:10.1007/978-3-030-63277-9_3 · Cited by 4
Zhang, X., Liu, J., Wang, Q., Chen, H., Yan, Y., Xiang, X., Shen, S., & Feng, W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1450049 · Cited by 4
Shatla, M. M., & Faisal, A. (2021) · The Egyptian Family Medicine Journal/The Egyptian Family Medicine Journal · doi:10.21608/efmj.2021.26839.1022 · Cited by 4
Lin, L., Huang, Z., Liu, K., Tong, X., Zhang, Z., & Xue, Y. (2024) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s450638 · Cited by 3
Endocrinology for the hepatologist
Afraz, S., & Kapila, N. (2023) · Clinical Liver Disease · doi:10.1097/cld.0000000000000037 · Cited by 3
Repurposing levothyroxine for managing metabolic dysfunction-associated steatotic liver disease
Duntas, L. H., Pοlyzos, S. A., Gottwald‐Hostalek, U., Urgatz, B., & Yen, P. M. (2025) · Endocrine · doi:10.1007/s12020-025-04451-0 · Cited by 2
Self-citationZhang, X., Tripathi, M., Goh, C. T., Chan, C. S., Boelen, A., Yen, P. M., Singh, B. K., & Bruinstroop, E. (2026) · Aging Cell · doi:10.1111/acel.70600 · Cited by 2
Self-citationCause-and-effect relationship between thyroid and liver diseases
Bueverov, A. O., Bogomolov, P., Nechaeva, O., & Zilov, A. V. (2021) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2021-15-88-94 · Cited by 2
Non-alcoholic steatohepatitis in patients with endocrine pathology. Review
Ткач, С. М., & Чеверда, Т. Л. (2021) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2021-2-82 · Cited by 2
Nonalcoholic fatty liver disease
van Son, K. C., Holleboom, A. G., & Tushuizen, M. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822186-0.00024-9 · Cited by 2
Li, S., Wu, X., Yu, J., Jiang, J., Qi, R., Chen, B., & Li, Z. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s490347 · Cited by 1
Hu, X., Shi, W., Xu, G., Li, W., Yao, N., Yu, G., & Qu, J. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2026.1696331 · Cited by 1
Pοlyzos, S. A., Yen, P. M., & Duntas, L. H. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.03.098 · Cited by 1
Self-citationExercise-Induced Hepatic Mitochondrial Reprogramming Across Muscle–Gut–Thyroid Axes in MASLD/MASH
McCaffrey, J. M., & Ibdah, J. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146112 · Cited by 1
Miranda, J. P., Gana, J. C., Alberti, G., Galindo, K., Pereira, A. P. R., & Santos, J. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072980 · Cited by 1
Seifert, J., Ludwik, K. A., Vallone, V. B. F., von Kügelgen, N., Jahn, R., Köhrle, J., Stachelscheid, H., & Wirth, E. K. (2025) · Research Square · doi:10.21203/rs.3.rs-6595009/v1 · Cited by 1
Leow, M. K. S. (2019) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/137045
Self-citation
Metadata
- Authors
- Bruinstroop, E., Dalan, R., Cao, Y., Bee, Y. M., Chandran, K., Cho, L. W., Soh, S. B., Teo, E. K., Toh, S.-A., Leow, M. K. S., Sinha, R. A., Sadananthan, S. A., Michael, N., Stapleton, H. M., Leung, C., Angus, P. W., Patel, S. K., Burrell, L. M., Lim, S. C., Sum, C. F., Velan, S. S., & Yen, P. M.
- Affiliations
- Duke-NUS Medical School (SG)
- Nanyang Technological University (SG)
- Singapore Clinical Research Institute (SG)
- Singapore General Hospital (SG)
- Ng Teng Fong General Hospital (SG)
- Changi General Hospital (SG)
- National University Health System (SG)
- Agency for Science, Technology and Research (SG)
- Duke University (US)
- The University of Melbourne (AU)
- Khoo Teck Puat Hospital (SG)
- Corresponding author
- Yen, Paul M
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-04-27
- Volume
- 103
- Issue
- 7
- Pages
- 2698-2706
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2802921027
- Cited by
- 108
- References
- 39
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 18 · 2023: 18 · 2022: 12 · 2021: 16 · 2020: 11 · 2019: 10 · 2018: 2
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- National University of Singapore (submittedVersion)
- Funders
- Duke-NUS Medical School
- Koninklijke Nederlandse Akademie van Wetenschappen
- Medical Research Council
- National Health and Medical Research Council (629025, 1029990)
- National Medical Research Council
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- levothyroxine, non-alcoholic fatty liver disease, type 2 diabetes, thyroid hormone replacement, hepatic steatosis, thyroid-stimulating hormone, fatty acid beta-oxidation, visceral adipose tissue, subcutaneous adipose tissue, 1H NMR
- MeSH terms
- Adult, Diabetes Mellitus, Type 2, Humans, Lipids, Liver, Male, Middle Aged, Thyroxine, Treatment Outcome, Young Adult, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.